Individual differences in amygdala reactivity following nicotinic receptor stimulation in abstinent smokers

NeuroImage

Volumn 66, Issue , 2013, Pages 585-593

  Sutherland, Matthew T ^a   Carroll, Allison J ^a   Salmeron, Betty Jo ^a   Ross, Thomas J ^a   Hong, L Elliot ^b   Stein, Elliot A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Amygdala; Emotion; Functional magnetic resonance imaging (fMRI); Nicotine; Varenicline; Withdrawal

Indexed keywords

CHOLINERGIC RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; PLACEBO; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINE GUM; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ADRENERGIC STIMULATION; ADULT; AMYGDALOID NUCLEUS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; EMOTIONALITY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; NICOTINE REPLACEMENT THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROPENSITY SCORE; REACTION TIME; SMOKING CESSATION; TASK PERFORMANCE; TOBACCO DEPENDENCE; BRAIN MAPPING; CROSSOVER PROCEDURE; DRUG EFFECTS; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SMOKING; WITHDRAWAL SYNDROME; YOUNG ADULT;

ADULT; AMYGDALA; BENZAZEPINES; BRAIN MAPPING; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; RECEPTORS, NICOTINIC; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE CESSATION PRODUCTS; VARENICLINE; YOUNG ADULT;

EID: 84870374895     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.10.043     Document Type: Article

References (57)

1. Baker T.B., Piper M.E., McCarthy D.E., Majeskie M.R., Fiore M.C. Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol. Rev. 2004, 111:33-51.
2. Bigos K.L., Pollock B.G., Aizenstein H.J., Fisher P.M., Bies R.R., Hariri A.R. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology 2008, 33:3221-3225.
3. Chase H.W., Eickhoff S.B., Laird A.R., Hogarth L. The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis. Biol. Psychiatry 2011, 70:785-793.
4. Cox R.W. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput. Biomed. Res. 1996, 29:162-173.
5. Evatt D.P., Kassel J.D. Smoking, arousal, and affect: the role of anxiety sensitivity. J. Anxiety Disord. 2010, 24:114-123.
6. Faessel H.M., Gibbs M.A., Clark D.J., Rohrbacher K., Stolar M., Burstein A.H. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J. Clin. Pharmacol. 2006, 46:1439-1448.
7. Franklin T., Wang Z., Suh J.J., Hazan R., Cruz J., Li Y., Goldman M., Detre J.A., O'Brien C.P., Childress A.R. Effects of varenicline on smoking cue-triggered neural and craving responses. Arch. Gen. Psychiatry 2011, 68:516-526.
8. Franklin T.R., Wang Z., Li Y., Suh J.J., Goldman M., Lohoff F.W., Cruz J., Hazan R., Jens W., Detre J.A., Berrettini W., O'Brien C.P., Childress A.R. Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict. Biol. 2011, 16:308-322.
9. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., Watsky E.J., Gong J., Williams K.E., Reeves K.R., Grp V.P.S. Varenicline, an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation - a randomized controlled trial. JAMA 2006, 296:47-55.
10. Greenwood P.M., Parasuraman R., Espeseth T. A cognitive phenotype for a polymorphism in the nicotinic receptor gene CHRNA4. Neurosci. Biobehav. Rev. 2012, 36:1331-1341.
11. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002, 297:400-403.
12. Hariri A.R., Tessitore A., Mattay V.S., Fera F., Weinberger D.R. The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage 2002, 17:317-323.
13. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The fagerstrom test for nicotine dependence - a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
14. Heishman S.J., Taylor R.C., Henningfield J.E. Nicotine and smoking: a review of effects on human performance. Exp. Clin. Psychopharmacol. 1994, 2:345-395.
15. Hughes J.R. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob. Res. 2007, 9:315-327.
16. Janes A.C., Pizzagalli D.A., Richardt S., Frederick B.D., Chuzi S., Pachas G., Culhane M.A., Holmes A.J., Fava M., Evins A.E., Kaufman M.J. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol. Psychiatry 2010, 67:722-729.
17. Jasinska A.J., Chua H.F., Ho S.S., Polk T.A., Rozek L.S., Strecher V.J. Amygdala response to smoking-cessation messages mediates the effects of serotonin transporter gene variation on quitting. Neuroimage 2012, 60:766-773.
18. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., Billing C.B., Gong J., Reeves K.R. Efficacy of varenicline, an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation - a randomized controlled trial. JAMA 2006, 296:56-63.
19. Kassel J.D., Stroud L.R., Paronis C.A. Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking. Psychol. Bull. 2003, 129:270-304.
20. Kleykamp B.A., Jennings J.M., Eissenberg T. Effects of transdermal nicotine and concurrent smoking on cognitive performance in tobacco-abstinent smokers. Exp. Clin. Psychopharmacol. 2011, 19:75-84.
21. Koob G.F. Brain stress systems in the amygdala and addiction. Brain Res. 2009, 1293:61-75.
22. Koob G.F., Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat. Neurosci. 2005, 8:1442-1444.
23. Kriegeskorte N., Simmons W.K., Bellgowan P.S.F., Baker C.I. Circular analysis in systems neuroscience: the dangers of double dipping. Nat. Neurosci. 2009, 12:535-540.
24. Kuhn S., Gallinat J. Common biology of craving across legal and illegal drugs - a quantitative meta-analysis of cue-reactivity brain response. Eur. J. Neurosci. 2011, 33:1318-1326.
25. Kukolja J., Schlapfer T.E., Keysers C., Klingmuller D., Maier W., Fink G.R., Hurlemann R. Modeling a negative response bias in the human amygdala by noradrenergic-glucocorticoid interactions. J. Neurosci. 2008, 28:12868-12876.
26. Labuschagne I., Phan K.L., Wood A., Angstadt M., Chua P., Heinrichs M., Stout J.C., Nathan P.J. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 2010, 35:2403-2413.
27. Lee D.C., Perkins K.A., Zimmerman E., Robbins G., Kelly T.H. Effects of 24 hours of tobacco withdrawal and subsequent tobacco smoking among low and high sensation seekers. Nicotine Tob. Res. 2011, 13:943-954.
28. Li Y.F., LaCroix C., Freeling J. Cytisine induces autonomic cardiovascular responses via activations of different nicotinic receptors. Auton. Neurosci. 2010, 154:14-19.
29. Loughead J., Wileyto E.P., Valdez J.N., Sanborn P., Tang K., Strasser A.A., Ruparel K., Ray R., Gur R.C., Lerman C. Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Mol. Psychiatry 2009, 14:820-826.
30. Loughead J., Ray R., Wileyto E.P., Ruparel K., Sanborn P., Siegel S., Gur R.C., Lerman C. Effects of the alpha 4 beta 2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol. Psychol. 2010, 67:715-721.
31. Loughead J., Ray R., Wileyto E.P., Ruparel K., O'Donnell G.P., Senecal N., Siegel S., Gur R.C., Lerman C. Brain activity and emotional processing in smokers treated with varenicline. Addict. Biol. 2011, 10.1111/j.1369-1600.2011.00324.x.
32. Mihalak K.B., Carroll F.I., Luetje C.W. Varenicline is a partial agonist at alpha 4 beta 2 and a full agonist at alpha 7 neuronal nicotinic receptors. Mol. Pharmacol. 2006, 70:801-805.
33. Mihov M., Hurlemann R. Altered amygdala function in nicotine addiction: insights from human neuroimaging studies. Neuropsychologia 2012, 50:1719-1729.
34. Myers C.S., Taylor R.C., Moolchan E.T., Heishman S.J. Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology 2008, 33:588-598.
35. Newhouse P.A., Potter A., Singh A. Effects of nicotinic stimulation on cognitive performance. Curr. Opin. Pharmacol. 2004, 4:36-46.
36. Palmer K.J., Buckley M.M., Faulds D. Transdermal nicotine - a review of Its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992, 44:498-529.
37. Patterson F., Jepson C., Strasser A.A., Loughead J., Perkins K.A., Gur R.C., Frey J.M., Siegel S., Lerman C. Varenicline improves mood and cognition during smoking abstinence. Biol. Psychol. 2009, 65:144-149.
38. Patterson F., Jepson C., Loughead J., Perkins K., Strasser A.A., Siegel S., Frey J., Gur R., Lerman C. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend. 2010, 106:61-64.
39. Paulus M.P., Feinstein J.S., Castillo G., Simmons A.N., Stein M.B. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch. Gen. Psychiatry 2005, 62:282-288.
40. Phelps E.A., LeDoux J.E. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 2005, 48:175-187.
41. Piasecki T.M. Relapse to smoking. Clin. Psychol. Rev. 2006, 26:196-215.
42. Piper M.E., Schlam T.R., Cook J.W., Sheffer M.A., Smith S.S., Loh W.Y., Bolt D.M., Kim S.Y., Kaye J.T., Hefner K.R., Baker T.B. Tobacco withdrawal components and their relations with cessation success. Psychopharmacology (Berl) 2011, 216:569-578.
43. Pourtois G., Vocat R., N'Diaye K., Spinelli L., Seeck M., Vuilleumier P. Errors recruit both cognitive and emotional monitoring systems: Simultaneous intracranial recordings in the dorsal anterior cingulate gyrus and amygdala combined with fMRI. Neuropsychologia 2010, 48:1144-1159.
44. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., Williams K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha(4)beta(2) nACh receptors for smoking cessation. Trends Pharmacol. Sci. 2007, 28:316-325.
45. Rollema H., Hajos M., Seymour P.A., Kozak R., Majchrzak M.J., Guanowsky V., Horner W.E., Chapin D.S., Hoffmann W.E., Johnson D.E., Mclean S., Freeman J., Williams K.E. Preclinical pharmacology of the alpha 4 beta 2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem. Pharmacol. 2009, 78:813-824.
46. Rose J.E., Behm F.M., Westman E.C., Mathew R.J., London E.D., Hawk T.C., Turkington T.G., Coleman R.E. PET studies of the influences of nicotine on neural systems in cigarette smokers. Am. J. Psychiatry 2003, 160:323-333.
47. Rose J.E., Behm F.M., Salley A.N., Bates J.E., Coleman R.E., Hawk T.C., Turkington T.G. Regional brain activity correlates of nicotine dependence. Neuropsychopharmacology 2007, 32:2441-2452.
48. Rukstalis M., Jepson C., Patterson F., Lerman C. Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. J. Subst. Abuse Treat. 2005, 28:297-304.
49. Sergerie K., Chochol C., Armony J.L. The role of the amygdala in emotional processing: a quantitative meta-analysis of functional neuroimaging studies. Neurosci. Biobehav. Rev. 2008, 32:811-830.
50. Smolka M.N., Buhler M., Klein S., Zimmermann U., Mann K., Heinz A., Braus D.F. Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology (Berl) 2006, 184:577-588.
51. Sofuoglu M., Herman A.I., Mooney M., Waters A.J. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl) 2009, 207:153-162.
52. SRNT-Subcommittee Biochemical verification of tobacco use and cessation. Nicotine Tob. Res. 2002, 4:149-159.
53. van Marle H.J.F., Tendolkar I., Urner M., Verkes R.J., Fernandez G., van Wingen G. Subchronic duloxetine administration alters the extended amygdala circuitry in healthy individuals. Neuroimage 2011, 55:825-831.
54. Wang Z., Faith M., Patterson F., Tang K., Kerrin K., Wileyto E.P., Detre J.A., Lerman C. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. J. Neurosci. 2007, 27:14035-14040.
55. Winterer G., Mittelstrass K., Giegling I., Lamina C., Fehr C., Brenner H., Breitling L.P., Nitz B., Raum E., Muller H., Gallinat J., Gal A., Heim K., Prokisch H., Meitinger T., Hartmann A.M., Moller H.J., Gieger C., Wichmann H.E., Illig T., Dahmen N., Rujescu D. Risk gene variants for nicotine dependence in the CHRNA5-CHRNA3-CHRNB4 cluster are associated with cognitive performance. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:1448-1458.
56. Wise R.A., Wang B., You Z.B. Cocaine serves as a peripheral interoceptive conditioned stimulus for central glutamate and dopamine release. PLoS One 2008, 3:e2846.
57. Zubieta J.K., Heitzeg M.M., Xu Y.J., Koeppe R.A., Ni L.S., Guthrie S., Domino E.F. Regional cerebral blood flow responses to smoking in tobacco smokers after overnight abstinence. Am. J. Psychiatry 2005, 162:567-577.